Hepatitis C treatment in combination with amiodarone: risk of severe bradycardia

Patients receiving combination therapy with simeprevir (Olysio) and sofosbuvir (Sovaldi) should avoid concomitant use of amiodarone, unless other antiarrhythmics cannot be given.

Following the May issue of Drug Safety Update, the MHRA has extended its advice regarding the use of sofosbuvir combination therapy with amiodarone, to now include simeprevir.

Advice for monitoring patients receiving concomitant amiodarone and with cardiac rhythm disorders and hepatitis C can be found here.

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.